Patents by Inventor Scott Jeffrey Kemp

Scott Jeffrey Kemp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRON OXIDE NANOPARTICLES AND THEIR SYNTHESIS BY CONTROLLED OXIDATION
    Publication number: 20180280545
    Abstract: Disclosed herein are iron oxide nanoparticles having an iron (II) content in a metastable state that is intermediate the iron (II) content of wüstite and magnetite. The disclosed iron oxide nanoparticles exhibit unexpectedly beneficial magnetic properties (e.g., saturation magnetization) resulting from both the size of the nanoparticles and the iron (II) content. Accordingly, the iron oxide nanoparticles are attractive for magnetic imaging applications, such as magnetic particle imaging. Methods of forming the iron oxide nanoparticles are also provided, such methods including a controlled oxidation step wherein a small amount (e.g., 1%) of gaseous oxygen is exposed to wüstite nanoparticles for a defined period of time sufficient to partially oxidize the wüstite but prevent conversion entirely to magnetite. Finally, methods of using the iron oxide nanoparticles are also provided. Representative methods include magnetic particle imaging, magnetic resonance imaging, and hyperthermia.
    Type: Application
    Filed: October 30, 2015
    Publication date: October 4, 2018
    Applicant: University of Washington
    Inventors: Kannan M. Krishnan, Amit Praful Khandhar, Richard M. Ferguson, Scott Jeffrey Kemp
  • NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20110117057
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: December 20, 2010
    Publication date: May 19, 2011
    Applicants: SCHERING CORPORATION, DENDREON CORPORATION
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7595299
    Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: September 29, 2009
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil Saksena, Viyyoor M. Girijavallabhan, Stephane L. Bogen, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Yi-Tsung Liu, Tin-Yau Chan, Zhaoning Zhu, Ashok Arasappan, Kevin X. Chen, Srikanth Venkatraman, Tejal Parekh, Patrick A. Pinto, Bama Santhanam, F. George Njoroge, Ashit K. Ganguly, Henry A. Vaccaro, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7244721
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: July 17, 2007
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. Mc Cormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang, Jesse K. Wong, Latha G. Nair
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7169760
    Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: January 30, 2007
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Stephane L. Bogen, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. Mc Cormick, Haiyan Wang, Russell E. Pike, Yi-Tsung Liu, Tin-Yau Chan, Zhaoning Zhu, Ashok Arasappan, Kevin X. Chen, Srinkanth Venkatraman, Tejal Parekh, Patrick A. Pinto, Bama Santhanam, F. George Njoroge, Ashit K. Ganguly, Henry A. Vaccaro, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7012066
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: March 14, 2006
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. Mc Cormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    Publication number: 20040254117
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: July 19, 2001
    Publication date: December 16, 2004
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 6800434
    Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: October 5, 2004
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Yi-Tsung Liu, Ashok Arasappan, Tejal Parekh, Patrick A. Pinto, F. George Njoroge, Ashit K. Ganguly, Terence K. Brunck, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby
  • Non-convalent thrombin inhibitors
    Patent number: 6777431
    Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: August 17, 2004
    Assignee: Corvas International, Inc.
    Inventors: Daniel Vanna Siev, Joseph Edward Semple, Mallareddy Komandla, John Eugene Reiner, Scott Jeffrey Kemp
  • Conjugates activated by cell surface proteases and therapeutic uses thereof
    Publication number: 20040001801
    Abstract: Conjugates, compositions and methods for treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases, are provided. The conjugates for use in the compositions and methods are peptidic conjugates that contain therapeutic, including cytotoxic, agents.
    Type: Application
    Filed: May 23, 2002
    Publication date: January 1, 2004
    Applicant: Corvas International, Inc.
    Inventors: Edwin L. Madison, Joseph Edward Semple, George P. Vlasuk, Scott Jeffrey Kemp, Mallareddy Komandla, Daniel Vanna Siev
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    Publication number: 20030216325
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: July 19, 2001
    Publication date: November 20, 2003
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry A. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang
  • Novel non-convalent thrombin inhibitors
    Publication number: 20030092679
    Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    Type: Application
    Filed: July 13, 2001
    Publication date: May 15, 2003
    Inventors: Daniel Vanna Siev, Joseph Edward Semple, Mallareddy Komandla, John Eugene Reiner, Scott Jeffrey Kemp
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    Publication number: 20030036501
    Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: July 19, 2001
    Publication date: February 20, 2003
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin E. Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Yi-Tsung Liu, Ashok Arasappan, Tejal Parekh, Patrick A. Pinto, F. George Njoroge, Ashit K. Ganguly, Terence K. Brunck, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby
  • Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
    Publication number: 20020160962
    Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Application
    Filed: July 19, 2001
    Publication date: October 31, 2002
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Stephane L. Bogen, Raymond G. Lovey, Edwin E. Jao, Frank Bennett, Jinping L. Mc Cormick, Haiyan Wang, Russell E. Pike, Yi-Tsung Liu, Tin-Yau Chan, Zhaoning Zhu, Ashok Arasappan, Kevin X. Chen, Srikanth Venkatraman, Tejal Parekh, Patrick A. Pinto, Bama Santhanam, F. George Njoroge, Ashit K. Ganguly, Henry A. Vaccaro, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: RE43298
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: April 3, 2012
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry M. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang